Mechanisms utilized by feline adipose-derived mesenchymal stem cells to inhibit T lymphocyte proliferation
Open Access
- 25 June 2019
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 10 (1) , 1-12
Abstract
Feline adipose-derived mesenchymal stem cells (ASCs) have been successfully used in clinical trials for the treatment of immune-mediated diseases with T cell dysregulation. However, the immunomodulatory pathways utilized by feline ASCs to suppress T cell activation have not been fully determined. We investigated the mechanisms used by feline ASCs to inhibit T cell proliferation, including the soluble factors and the cell-cell contact ligands responsible for ASC-T cell interaction. The immunomodulatory activity of feline ASCs was evaluated via cell cycle analysis and in vitro mixed leukocyte reaction using specific immunomodulatory inhibitors. Cell-cell interactions were assessed with static adhesion assays, also with inhibitors. Feline ASCs decrease T cell proliferation by causing cell cycle arrest in G0–G1. Blocking prostaglandin (PGE2), but not IDO, partially restored lymphocyte proliferation. Although PDL-1 and CD137L are both expressed on activated feline ASCs, only the interaction of intercellular adhesion molecule 1 (ICAM-1, CD54) with its ligand, lymphocyte function-associated antigen 1 (LFA-1, CD11a/CD18), was responsible for ASC-T cell adhesion. Blocking this interaction reduced cell-cell adhesion and mediator (IFN-γ) secretion and signaling. Feline ASCs utilize PGE2 and ICAM-1/LFA-1 ligand interaction to inhibit T cell proliferation with a resultant cell cycle arrest in G0–G1. These data further elucidate the mechanisms by which feline ASCs interact with T cells, help define appropriate T cell-mediated disease targets in cats that may be amenable to ASC therapy, and may also inform potential translational models for human diseases.Keywords
Funding Information
- Winn Feline Foundation (N/A)
This publication has 62 references indexed in Scilit:
- Therapeutic Efficacy of Fresh, Allogeneic Mesenchymal Stem Cells for Severe Refractory Feline Chronic GingivostomatitisStem Cells Translational Medicine, 2017
- Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated ImmunosuppressionStem Cells, 2016
- Concise Review: Stem Cell Trials Using Companion Animal Disease ModelsStem Cells, 2016
- Species Variation in the Mechanisms of Mesenchymal Stem Cell-Mediated ImmunosuppressionStem Cells, 2009
- Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric OxideCell Stem Cell, 2008
- ICAM-1 co-stimulates target cells to facilitate antigen presentationCurrent Opinion in Immunology, 2005
- Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathwayEuropean Journal of Immunology, 2005
- T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppressionJournal of Biomedical Science, 2005
- Characterization and functionality of cell surface molecules on human mesenchymal stem cellsJournal of Biomedical Science, 2003
- Regulation of intercellular adhesion molecule-1 (CD54) gene expressionJournal of Leukocyte Biology, 1999